 |
ICON Group International, Inc. (an IG Ltd Company)
|
Industry Reports ICON Group International, Inc. (an IG Ltd Company) |
|
| Title | Pages | Price | Order/View |
|---|---|---|---|
The 2009-2014 World Outlook for Ophthalmic Pharmaceutical Drugs | 196 | $795 |  |
The 2009-2014 World Outlook for Ace Inhibitor Vasodilator Pharmaceuticals | 188 | $795 | |
The 2009-2014 World Outlook for Alimentary and Metabolism Pharmaceuticals | 187 | $795 | |
The 2009-2014 World Outlook for Antacid Pharmaceutical Preparations Excluding Effervescent Salicylate Analgesics | 197 | $795 | |
The 2009-2014 World Outlook for Anti-Arrhythmic Vasodilator Pharmaceuticals | 186 | $795 | |
The 2009-2014 World Outlook for Antibacterial and Antiseptic Pharmaceuticals | 188 | $795 | |
The 2009-2014 World Outlook for Anticoagulant Pharmaceutical Preparations | 187 | $795 | |
The 2009-2014 World Outlook for Antidepressant Pharmaceuticals | 186 | $795 | |
The 2009-2014 World Outlook for Antidiarrheal Pharmaceutical Preparations Excluding Narcotics | 188 | $795 | |
The 2009-2014 World Outlook for Antifungal Pharmaceuticals | 188 | $795 | |
The 2009-2014 World Outlook for Anti-Infective Pharmaceutical Preparations Affecting Amebacides and Trichomonicides | 199 | $795 | |
The 2009-2014 World Outlook for Anti-Infective Pharmaceutical Preparations Affecting Anthelminics | 189 | $795 | |
The 2009-2014 World Outlook for Antimalarial (plasmodicide) Pharmaceuticals | 187 | $795 | |
The 2009-2014 World Outlook for Anti-Neoplastic Pharmaceutical Agents | 187 | $795 | |
The 2009-2014 World Outlook for Anti-Neoplastic Radioactive Isotopes for Internal Pharmaceutical Use | 187 | $795 | |
The 2009-2014 World Outlook for Antispasmodic and Anticholinergic Pharmaceutical Preparations Excluding Synthetic and H2 Blocking Agents | 199 | $795 | |
The 2009-2014 World Outlook for Antispasmodic and Antisecretory Pharmaceutical Preparations | 188 | $795 | |
The 2009-2014 World Outlook for Antitubercular Pharmaceuticals Excluding Tuberculostatic Isoniazid (isonicotinic Acid Hydrazide) Preparations | 198 | $795 | |
The 2009-2014 World Outlook for Beta-Receptor Blocking Agent Hypotensive Pharmaceuticals | 186 | $795 | |
The 2009-2014 World Outlook for Bronchial Dilator and Anti-Asthmatic Pharmaceutical Preparations | 189 | $795 | |
The 2009-2014 World Outlook for Calcium Channel Blocker Vasodilator Pharmaceuticals | 187 | $795 | |
The 2009-2014 World Outlook for Cancer Therapy Pharmaceuticals | 187 | $795 | |
The 2009-2014 World Outlook for Coronary Vasodilator Pharmaceuticals | 186 | $795 | |
The 2009-2014 World Outlook for Enema Specialty Laxative Pharmaceutical Preparations | 188 | $795 | |
The 2009-2014 World Outlook for Estrogen Hormones and Synthetic Substitute Pharmaceuticals | 186 | $795 | |
The 2009-2014 World Outlook for Fecal Softener Laxative Pharmaceutical Preparations | 187 | $795 | |
The 2009-2014 World Outlook for Food-Grade Gelatin Excluding Pharmaceutical and Photographic Gelatin | 191 | $795 | |
The 2009-2014 World Outlook for Insulins and Anti-Diabetic Hormones and Synthetic Substitute Pharmaceuticals | 194 | $795 | |
The 2009-2014 World Outlook for Irritant Laxative Pharmaceutical Preparations | 185 | $795 | |
The 2009-2014 World Outlook for Local and Topical Corticoids, Hormones, and Synthetic Hormone Substitute Pharmaceuticals | 198 | $795 | |
The 2009-2014 World Outlook for Logistics for the Pharmaceutical Industry | 187 | $795 | |
The 2009-2014 World Outlook for Manufacturing Pharmaceutical and Medicinal Products | 188 | $795 | |
The 2009-2014 World Outlook for Manufacturing Pharmaceutical Preparations | 189 | $795 | |
The 2009-2014 World Outlook for Opium and Opium-Derivative Narcotic Internal Analgesic and Antipyretic Pharmaceutical Preparations | 199 | $795 | |
The 2009-2014 World Outlook for Oral Contraceptive Preparations of Hormones and Synthetic Substitute Pharmaceuticals | 199 | $795 | |
The 2009-2014 World Outlook for Oxytocic Pharmaceutical Preparations | 187 | $795 | |
The 2009-2014 World Outlook for Peripheral Vasodilator Pharmaceuticals | 186 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical Preparations Acting on the Cardiovascular System | 191 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical Preparations Acting on the Digestive or Genito-Urinary Systems | 195 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical Preparations Acting on the Human Cardiovascular System | 193 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical Preparations Acting on the Human Digestive and Genitourinary Systems | 203 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical Preparations Acting on the Respiratory System | 189 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical Preparations Acting on the Skin | 188 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical Preparations Affecting the Central Nervous System and Sense Organs | 197 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical Preparations for Human Use Acting on Skin | 189 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical Preparations for Human Use Acting on the Cardiovascular System | 198 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical Preparations for Human Use Acting on the Central Nervous System and the Sense Organs | 201 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical Preparations for Human Use Acting on the Digestive or the Genito-Urinary Systems | 201 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical Preparations for Human Use Acting on the Respiratory System | 195 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical Preparations for Human Use Affecting Neoplasms, the Endocrine System, and Metabolic Diseases | 200 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical Preparations for Human Use Affecting Parasitic and Ineffective Diseases Excluding Diagnostics | 197 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical Preparations for Human Use Affecting Parasitic and Infectious Diseases Excluding Diagnostics | 203 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical Preparations for Veterinary Use | 189 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical Preparations for Veterinary Use Excluding Diagnostics | 191 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical Vitamin, Nutrient, and Hematinic Preparations | 189 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical Vitamin, Nutrient, and Hematinic Preparations for Human Use | 194 | $795 | |
The 2009-2014 World Outlook for Pharmaceutical-Grade Gelatin Excluding Unfilled Capsules | 188 | $795 | |
The 2009-2014 World Outlook for Pharmaceuticals Affecting Neoplasms, the Endocrine System, and Metabolic Diseases | 199 | $795 | |
The 2009-2014 World Outlook for Rauwolfia-Alkaloid Preparation and Rauwolfia-Diuretic Combination Hypotensive Pharmaceuticals | 197 | $795 | |
The 2009-2014 World Outlook for Saline Laxative Pharmaceutical Preparations | 187 | $795 | |
The 2009-2014 World Outlook for Skeletal Muscle Relaxant Pharmaceutical Preparations | 187 | $795 | |
The 2009-2014 World Outlook for Sulfonamide Pharmaceuticals Excluding Sulfa-Antibiotic Combinations | 188 | $795 | |
The 2009-2014 World Outlook for Synthetic Antispasmodics and Anticholinergics Pharmaceutical Preparations | 191 | $795 | |
The 2009-2014 World Outlook for Synthetic Narcotic Pharmaceutical Preparations | 187 | $795 | |
The 2009-2014 World Outlook for Systemic Antibiotic-Sulfonamide Combination Pharmaceuticals | 187 | $795 | |
The 2009-2014 World Outlook for Systemic Antiviral Pharmaceuticals | 187 | $795 | |
The 2009-2014 World Outlook for Systemic Broad-And Medium-Spectrum Antibiotic Pharmaceutical Preparations of Injectable, Semisynthetic Single Penicillins | 199 | $795 | |
The 2009-2014 World Outlook for Systemic Broad-And Medium-Spectrum Antibiotic Pharmaceutical Preparations of Semisynthetic Single Penicillins Excluding Injectable Forms | 198 | $795 | |
The 2009-2014 World Outlook for Thyroid and Anti-Thyroid Preparations of Hormones and Synthetic Substitute Pharmaceuticals | 198 | $795 | |
The 2009-2014 World Outlook for Topical Antibiotic Pharmaceuticals | 187 | $795 | |
The 2009-2014 World Outlook for Tuberculostatic Isoniazid (isonicotinic Acid Hydrazide) Pharmaceuticals | 191 | $795 | |
The 2009-2014 World Outlook for Urinary Antibacterials and Antiseptic Pharmaceutical Preparations | 189 | $795 | |
The 2009-2014 World Outlook for Veterinary Antibiotic Pharmaceuticals Excluding Penicillins and Tetracyclines | 194 | $795 | |
The 2009-2014 World Outlook for Veterinary Pharmaceutical Preparations of Anesthetics | 187 | $795 | |
The 2009-2014 World Outlook for Veterinary Pharmaceutical Preparations of Anthelmintics | 188 | $795 | |
The 2009-2014 World Outlook for Veterinary Pharmaceutical Preparations of Antibiotic Penicillins | 187 | $795 | |
The 2009-2014 World Outlook for Veterinary Pharmaceutical Preparations of Antibiotic Tetracyclines | 188 | $795 | |
The 2009-2014 World Outlook for Veterinary Pharmaceutical Preparations of Antiseptics, Wound Dressings, and Fungicides | 199 | $795 | |
The 2009-2014 World Outlook for Veterinary Pharmaceutical Preparations of External Parasiticides | 186 | $795 | |
The 2009-2014 World Outlook for Veterinary Pharmaceutical Preparations of Hemostatics | 189 | $795 | |
The 2009-2014 World Outlook for Veterinary Pharmaceutical Preparations of Intravenous Solutions and Electrolytes | 197 | $795 | |
The 2009-2014 World Outlook for Veterinary Pharmaceutical Preparations of Sulfonamides | 188 | $795 | |
The 2009-2014 World Outlook for Veterinary Pharmaceutical Preparations of Tranquilizers and Ataractics | 190 | $795 | |
The 2009-2014 World Outlook for Veterinary Pharmaceutical Preparations of Vitamins and Minerals | 188 | $795 | |
The 2009-2014 World Outlook for Veterinary Pharmaceuticals, Medicinal Premixes, and Medicated Pet Care Products Excluding Diagnostic Preparations and Pet Flea-And-Tick Products | 200 | $795 | |
The 2009-2014 World Outlook for Glace, Candied, and Crystallized Fruits, Fruit Peels, Nuts, Marshmallow Cream, Cough Drops Excluding Pharmaceutical Type, and Other Confectionery-Type Products | 202 | $795 | |
| Title | Pages | Price | Order/View |
|---|---|---|---|
The 2009-2014 Outlook for Ophthalmic Pharmaceutical Drugs in Africa & the Middle East | 75 | $325 | |
The 2009-2014 Outlook for Ophthalmic Pharmaceutical Drugs in Asia | 38 | $325 | |
The 2009-2014 Outlook for Ophthalmic Pharmaceutical Drugs in Europe | 54 | $325 | |
The 2009-2014 Outlook for Ophthalmic Pharmaceutical Drugs in Latin America | 35 | $325 | |
The 2009-2014 Outlook for Ophthalmic Pharmaceutical Drugs in North America & the Caribbean | 37 | $325 | |
The 2009-2014 Outlook for Ophthalmic Pharmaceutical Drugs in Oceana | 34 | $325 | |
| Country | Title | Pages | Price | Order/View |
|---|---|---|---|---|
| India | The 2009-2014 Outlook for Ace Inhibitor Vasodilator Pharmaceuticals in India | 319 | $495 | |
| India | The 2009-2014 Outlook for Alimentary and Metabolism Pharmaceuticals in India | 319 | $495 | |
| India | The 2009-2014 Outlook for Antacid Pharmaceutical Preparations Excluding Effervescent Salicylate Analgesics in India | 336 | $495 | |
| India | The 2009-2014 Outlook for Anti-Arrhythmic Vasodilator Pharmaceuticals in India | 318 | $495 | |
| India | The 2009-2014 Outlook for Antibacterial and Antiseptic Pharmaceuticals in India | 318 | $495 | |
| India | The 2009-2014 Outlook for Anticoagulant Pharmaceutical Preparations in India | 319 | $495 | |
| India | The 2009-2014 Outlook for Antidepressant Pharmaceuticals in India | 319 | $495 | |
| India | The 2009-2014 Outlook for Antidiarrheal Pharmaceutical Preparations Excluding Narcotics in India | 335 | $495 | |
| India | The 2009-2014 Outlook for Antifungal Pharmaceuticals in India | 319 | $495 | |
| India | The 2009-2014 Outlook for Anti-Infective Pharmaceutical Preparations Affecting Amebacides and Trichomonicides in India | 180 | $495 | |
| India | The 2009-2014 Outlook for Anti-Infective Pharmaceutical Preparations Affecting Anthelminics in India | 111 | $495 | |
| India | The 2009-2014 Outlook for Antimalarial (plasmodicide) Pharmaceuticals in India | 212 | $495 | |
| India | The 2009-2014 Outlook for Anti-Neoplastic Pharmaceutical Agents in India | 319 | $495 | |
| India | The 2009-2014 Outlook for Anti-Neoplastic Radioactive Isotopes for Internal Pharmaceutical Use in India | 217 | $495 | |
| India | The 2009-2014 Outlook for Antispasmodic and Anticholinergic Pharmaceutical Preparations Excluding Synthetic and H2 Blocking Agents in India | 209 | $495 | |
| India | The 2009-2014 Outlook for Antispasmodic and Antisecretory Pharmaceutical Preparations in India | 332 | $495 | |
| India | The 2009-2014 Outlook for Antitubercular Pharmaceuticals Excluding Tuberculostatic Isoniazid (isonicotinic Acid Hydrazide) Preparations in India | 157 | $495 | |
| India | The 2009-2014 Outlook for Beta-Receptor Blocking Agent Hypotensive Pharmaceuticals in India | 313 | $495 | |
| India | The 2009-2014 Outlook for Bronchial Dilator and Anti-Asthmatic Pharmaceutical Preparations in India | 335 | $495 | |
| India | The 2009-2014 Outlook for Calcium Channel Blocker Vasodilator Pharmaceuticals in India | 323 | $495 | |
| India | The 2009-2014 Outlook for Cancer Therapy Pharmaceuticals in India | 314 | $495 | |
| India | The 2009-2014 Outlook for Coronary Vasodilator Pharmaceuticals in India | 319 | $495 | |
| India | The 2009-2014 Outlook for Enema Specialty Laxative Pharmaceutical Preparations in India | 175 | $495 | |
| India | The 2009-2014 Outlook for Estrogen Hormones and Synthetic Substitute Pharmaceuticals in India | 332 | $495 | |
| India | The 2009-2014 Outlook for Fecal Softener Laxative Pharmaceutical Preparations in India | 206 | $495 | |
| India | The 2009-2014 Outlook for Food-Grade Gelatin Excluding Pharmaceutical and Photographic Gelatin in India | 307 | $495 | |
| India | The 2009-2014 Outlook for Glace, Candied, and Crystallized Fruits, Fruit Peels, Nuts, Marshmallow Cream, Cough Drops Excluding Pharmaceutical Type, and Other Confectionery-Type Products in India | 330 | $495 | |
| India | The 2009-2014 Outlook for Insulins and Anti-Diabetic Hormones and Synthetic Substitute Pharmaceuticals in India | 336 | $495 | |
| India | The 2009-2014 Outlook for Irritant Laxative Pharmaceutical Preparations in India | 297 | $495 | |
| India | The 2009-2014 Outlook for Local and Topical Corticoids, Hormones, and Synthetic Hormone Substitute Pharmaceuticals in India | 335 | $495 | |
| India | The 2009-2014 Outlook for Opium and Opium-Derivative Narcotic Internal Analgesic and Antipyretic Pharmaceutical Preparations in India | 336 | $495 | |
| India | The 2009-2014 Outlook for Oral Contraceptive Preparations of Hormones and Synthetic Substitute Pharmaceuticals in India | 335 | $495 | |
| India | The 2009-2014 Outlook for Oxytocic Pharmaceutical Preparations in India | 253 | $495 | |
| India | The 2009-2014 Outlook for Peripheral Vasodilator Pharmaceuticals in India | 243 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Cardiovascular System in India | 336 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Digestive or Genito-Urinary Systems in India | 336 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Human Cardiovascular System in India | 336 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Human Digestive and Genitourinary Systems in India | 337 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Respiratory System in India | 335 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Skin in India | 321 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical Preparations Affecting the Central Nervous System and Sense Organs in India | 336 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on Skin in India | 330 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on the Cardiovascular System in India | 336 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on the Central Nervous System and the Sense Organs in India | 338 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on the Digestive or the Genito-Urinary Systems in India | 336 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on the Respiratory System in India | 337 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Affecting Neoplasms, the Endocrine System, and Metabolic Diseases in India | 337 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Affecting Parasitic and Ineffective Diseases Excluding Diagnostics in India | 336 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Affecting Parasitic and Infectious Diseases Excluding Diagnostics in India | 337 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical Preparations for Veterinary Use Excluding Diagnostics in India | 336 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical Preparations for Veterinary Use in India | 322 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical Vitamin, Nutrient, and Hematinic Preparations for Human Use in India | 336 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical Vitamin, Nutrient, and Hematinic Preparations in India | 334 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceutical-Grade Gelatin Excluding Unfilled Capsules in India | 221 | $495 | |
| India | The 2009-2014 Outlook for Pharmaceuticals Affecting Neoplasms, the Endocrine System, and Metabolic Diseases in India | 337 | $495 | |
| India | The 2009-2014 Outlook for Rauwolfia-Alkaloid Preparation and Rauwolfia-Diuretic Combination Hypotensive Pharmaceuticals in India | 122 | $495 | |
| India | The 2009-2014 Outlook for Saline Laxative Pharmaceutical Preparations in India | 130 | $495 | |
| India | The 2009-2014 Outlook for Skeletal Muscle Relaxant Pharmaceutical Preparations in India | 322 | $495 | |
| India | The 2009-2014 Outlook for Sulfonamide Pharmaceuticals Excluding Sulfa-Antibiotic Combinations in India | 266 | $495 | |
| India | The 2009-2014 Outlook for Synthetic Antispasmodics and Anticholinergics Pharmaceutical Preparations in India | 162 | $495 | |
| India | The 2009-2014 Outlook for Synthetic Narcotic Pharmaceutical Preparations in India | 320 | $495 | |
| India | The 2009-2014 Outlook for Systemic Antibiotic-Sulfonamide Combination Pharmaceuticals in India | 160 | $495 | |
| India | The 2009-2014 Outlook for Systemic Antiviral Pharmaceuticals in India | 319 | $495 | |
| India | The 2009-2014 Outlook for Systemic Broad-And Medium-Spectrum Antibiotic Pharmaceutical Preparations of Injectable, Semisynthetic Single Penicillins in India | 270 | $495 | |
| India | The 2009-2014 Outlook for Systemic Broad-And Medium-Spectrum Antibiotic Pharmaceutical Preparations of Semisynthetic Single Penicillins Excluding Injectable Forms in India | 336 | $495 | |
| India | The 2009-2014 Outlook for Thyroid and Anti-Thyroid Preparations of Hormones and Synthetic Substitute Pharmaceuticals in India | 138 | $495 | |
| India | The 2009-2014 Outlook for Topical Antibiotic Pharmaceuticals in India | 316 | $495 | |
| India | The 2009-2014 Outlook for Tuberculostatic Isoniazid (isonicotinic Acid Hydrazide) Pharmaceuticals in India | 106 | $495 | |
| India | The 2009-2014 Outlook for Urinary Antibacterials and Antiseptic Pharmaceutical Preparations in India | 327 | $495 | |
| India | The 2009-2014 Outlook for Veterinary Antibiotic Pharmaceuticals Excluding Penicillins and Tetracyclines in India | 335 | $495 | |
| India | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Anesthetics in India | 169 | $495 | |
| India | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Anthelmintics in India | 327 | $495 | |
| India | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Antibiotic Penicillins in India | 239 | $495 | |
| India | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Antibiotic Tetracyclines in India | 175 | $495 | |
| India | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Antiseptics, Wound Dressings, and Fungicides in India | 277 | $495 | |
| India | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of External Parasiticides in India | 334 | $495 | |
| India | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Hemostatics in India | 103 | $495 | |
| India | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Intravenous Solutions and Electrolytes in India | 117 | $495 | |
| India | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Sulfonamides in India | 124 | $495 | |
| India | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Tranquilizers and Ataractics in India | 163 | $495 | |
| India | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Vitamins and Minerals in India | 313 | $495 | |
| India | The 2009-2014 Outlook for Veterinary Pharmaceuticals, Medicinal Premixes, and Medicated Pet Care Products Excluding Diagnostic Preparations and Pet Flea-And-Tick Products in India | 337 | $495 | |
| Japan | The 2009-2014 Outlook for Ace Inhibitor Vasodilator Pharmaceuticals in Japan | 141 | $495 | |
| Japan | The 2009-2014 Outlook for Alimentary and Metabolism Pharmaceuticals in Japan | 141 | $495 | |
| Japan | The 2009-2014 Outlook for Antacid Pharmaceutical Preparations Excluding Effervescent Salicylate Analgesics in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Anti-Arrhythmic Vasodilator Pharmaceuticals in Japan | 141 | $495 | |
| Japan | The 2009-2014 Outlook for Antibacterial and Antiseptic Pharmaceuticals in Japan | 141 | $495 | |
| Japan | The 2009-2014 Outlook for Anticoagulant Pharmaceutical Preparations in Japan | 141 | $495 | |
| Japan | The 2009-2014 Outlook for Antidepressant Pharmaceuticals in Japan | 141 | $495 | |
| Japan | The 2009-2014 Outlook for Antidiarrheal Pharmaceutical Preparations Excluding Narcotics in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Antifungal Pharmaceuticals in Japan | 141 | $495 | |
| Japan | The 2009-2014 Outlook for Anti-Infective Pharmaceutical Preparations Affecting Amebacides and Trichomonicides in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Anti-Infective Pharmaceutical Preparations Affecting Anthelminics in Japan | 160 | $495 | |
| Japan | The 2009-2014 Outlook for Antimalarial (plasmodicide) Pharmaceuticals in Japan | 141 | $495 | |
| Japan | The 2009-2014 Outlook for Anti-Neoplastic Pharmaceutical Agents in Japan | 141 | $495 | |
| Japan | The 2009-2014 Outlook for Anti-Neoplastic Radioactive Isotopes for Internal Pharmaceutical Use in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Antispasmodic and Anticholinergic Pharmaceutical Preparations Excluding Synthetic and H2 Blocking Agents in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Antispasmodic and Antisecretory Pharmaceutical Preparations in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Antitubercular Pharmaceuticals Excluding Tuberculostatic Isoniazid (isonicotinic Acid Hydrazide) Preparations in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Beta-Receptor Blocking Agent Hypotensive Pharmaceuticals in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Bronchial Dilator and Anti-Asthmatic Pharmaceutical Preparations in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Calcium Channel Blocker Vasodilator Pharmaceuticals in Japan | 159 | $495 | |
| Japan | The 2009-2014 Outlook for Cancer Therapy Pharmaceuticals in Japan | 141 | $495 | |
| Japan | The 2009-2014 Outlook for Coronary Vasodilator Pharmaceuticals in Japan | 141 | $495 | |
| Japan | The 2009-2014 Outlook for Enema Specialty Laxative Pharmaceutical Preparations in Japan | 159 | $495 | |
| Japan | The 2009-2014 Outlook for Estrogen Hormones and Synthetic Substitute Pharmaceuticals in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Fecal Softener Laxative Pharmaceutical Preparations in Japan | 153 | $495 | |
| Japan | The 2009-2014 Outlook for Food-Grade Gelatin Excluding Pharmaceutical and Photographic Gelatin in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Glace, Candied, and Crystallized Fruits, Fruit Peels, Nuts, Marshmallow Cream, Cough Drops Excluding Pharmaceutical Type, and Other Confectionery-Type Products in Japan | 174 | $495 | |
| Japan | The 2009-2014 Outlook for Insulins and Anti-Diabetic Hormones and Synthetic Substitute Pharmaceuticals in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Irritant Laxative Pharmaceutical Preparations in Japan | 141 | $495 | |
| Japan | The 2009-2014 Outlook for Local and Topical Corticoids, Hormones, and Synthetic Hormone Substitute Pharmaceuticals in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Opium and Opium-Derivative Narcotic Internal Analgesic and Antipyretic Pharmaceutical Preparations in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Oral Contraceptive Preparations of Hormones and Synthetic Substitute Pharmaceuticals in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Oxytocic Pharmaceutical Preparations in Japan | 141 | $495 | |
| Japan | The 2009-2014 Outlook for Peripheral Vasodilator Pharmaceuticals in Japan | 141 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Cardiovascular System in Japan | 171 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Digestive or Genito-Urinary Systems in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Human Cardiovascular System in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Human Digestive and Genitourinary Systems in Japan | 171 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Respiratory System in Japan | 172 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Skin in Japan | 142 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical Preparations Affecting the Central Nervous System and Sense Organs in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on Skin in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on the Cardiovascular System in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on the Central Nervous System and the Sense Organs in Japan | 172 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on the Digestive or the Genito-Urinary Systems in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on the Respiratory System in Japan | 171 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Affecting Neoplasms, the Endocrine System, and Metabolic Diseases in Japan | 171 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Affecting Parasitic and Ineffective Diseases Excluding Diagnostics in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Affecting Parasitic and Infectious Diseases Excluding Diagnostics in Japan | 171 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical Preparations for Veterinary Use Excluding Diagnostics in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical Preparations for Veterinary Use in Japan | 142 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical Vitamin, Nutrient, and Hematinic Preparations for Human Use in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical Vitamin, Nutrient, and Hematinic Preparations in Japan | 171 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceutical-Grade Gelatin Excluding Unfilled Capsules in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Pharmaceuticals Affecting Neoplasms, the Endocrine System, and Metabolic Diseases in Japan | 171 | $495 | |
| Japan | The 2009-2014 Outlook for Rauwolfia-Alkaloid Preparation and Rauwolfia-Diuretic Combination Hypotensive Pharmaceuticals in Japan | 169 | $495 | |
| Japan | The 2009-2014 Outlook for Saline Laxative Pharmaceutical Preparations in Japan | 141 | $495 | |
| Japan | The 2009-2014 Outlook for Skeletal Muscle Relaxant Pharmaceutical Preparations in Japan | 159 | $495 | |
| Japan | The 2009-2014 Outlook for Sulfonamide Pharmaceuticals Excluding Sulfa-Antibiotic Combinations in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Synthetic Antispasmodics and Anticholinergics Pharmaceutical Preparations in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Synthetic Narcotic Pharmaceutical Preparations in Japan | 141 | $495 | |
| Japan | The 2009-2014 Outlook for Systemic Antibiotic-Sulfonamide Combination Pharmaceuticals in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Systemic Antiviral Pharmaceuticals in Japan | 141 | $495 | |
| Japan | The 2009-2014 Outlook for Systemic Broad-And Medium-Spectrum Antibiotic Pharmaceutical Preparations of Injectable, Semisynthetic Single Penicillins in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Systemic Broad-And Medium-Spectrum Antibiotic Pharmaceutical Preparations of Semisynthetic Single Penicillins Excluding Injectable Forms in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Thyroid and Anti-Thyroid Preparations of Hormones and Synthetic Substitute Pharmaceuticals in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Topical Antibiotic Pharmaceuticals in Japan | 141 | $495 | |
| Japan | The 2009-2014 Outlook for Tuberculostatic Isoniazid (isonicotinic Acid Hydrazide) Pharmaceuticals in Japan | 145 | $495 | |
| Japan | The 2009-2014 Outlook for Urinary Antibacterials and Antiseptic Pharmaceutical Preparations in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Veterinary Antibiotic Pharmaceuticals Excluding Penicillins and Tetracyclines in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Anesthetics in Japan | 162 | $495 | |
| Japan | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Anthelmintics in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Antibiotic Penicillins in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Antibiotic Tetracyclines in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Antiseptics, Wound Dressings, and Fungicides in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of External Parasiticides in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Hemostatics in Japan | 143 | $495 | |
| Japan | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Intravenous Solutions and Electrolytes in Japan | 168 | $495 | |
| Japan | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Sulfonamides in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Tranquilizers and Ataractics in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Vitamins and Minerals in Japan | 170 | $495 | |
| Japan | The 2009-2014 Outlook for Veterinary Pharmaceuticals, Medicinal Premixes, and Medicated Pet Care Products Excluding Diagnostic Preparations and Pet Flea-And-Tick Products in Japan | 173 | $495 | |
| USA | The 2009-2014 Outlook for Alimentary and Metabolism Pharmaceuticals in the United States | 733 | $495 | |
| USA | The 2009-2014 Outlook for Antidepressant Pharmaceuticals in the United States | 731 | $495 | |
| USA | The 2009-2014 Outlook for Ace Inhibitor Vasodilator Pharmaceuticals in the United States | 733 | $495 | |
| USA | The 2009-2014 Outlook for Antacid Pharmaceutical Preparations Excluding Effervescent Salicylate Analgesics in the United States | 749 | $495 | |
| USA | The 2009-2014 Outlook for Anti-Arrhythmic Vasodilator Pharmaceuticals in the United States | 734 | $495 | |
| USA | The 2009-2014 Outlook for Antibacterial and Antiseptic Pharmaceuticals in the United States | 732 | $495 | |
| USA | The 2009-2014 Outlook for Anticoagulant Pharmaceutical Preparations in the United States | 732 | $495 | |
| USA | The 2009-2014 Outlook for Antidiarrheal Pharmaceutical Preparations Excluding Narcotics in the United States | 749 | $495 | |
| USA | The 2009-2014 Outlook for Antifungal Pharmaceuticals in the United States | 731 | $495 | |
| USA | The 2009-2014 Outlook for Anti-Infective Pharmaceutical Preparations Affecting Amebacides and Trichomonicides in the United States | 446 | $495 | |
| USA | The 2009-2014 Outlook for Anti-Infective Pharmaceutical Preparations Affecting Anthelminics in the United States | 244 | $495 | |
| USA | The 2009-2014 Outlook for Antimalarial (plasmodicide) Pharmaceuticals in the United States | 517 | $495 | |
| USA | The 2009-2014 Outlook for Anti-Neoplastic Pharmaceutical Agents in the United States | 731 | $495 | |
| USA | The 2009-2014 Outlook for Anti-Neoplastic Radioactive Isotopes for Internal Pharmaceutical Use in the United States | 525 | $495 | |
| USA | The 2009-2014 Outlook for Antispasmodic and Anticholinergic Pharmaceutical Preparations Excluding Synthetic and H2 Blocking Agents in the United States | 490 | $495 | |
| USA | The 2009-2014 Outlook for Antispasmodic and Antisecretory Pharmaceutical Preparations in the United States | 748 | $495 | |
| USA | The 2009-2014 Outlook for Antitubercular Pharmaceuticals Excluding Tuberculostatic Isoniazid (isonicotinic Acid Hydrazide) Preparations in the United States | 408 | $495 | |
| USA | The 2009-2014 Outlook for Beta-Receptor Blocking Agent Hypotensive Pharmaceuticals in the United States | 746 | $495 | |
| USA | The 2009-2014 Outlook for Bronchial Dilator and Anti-Asthmatic Pharmaceutical Preparations in the United States | 749 | $495 | |
| USA | The 2009-2014 Outlook for Calcium Channel Blocker Vasodilator Pharmaceuticals in the United States | 742 | $495 | |
| USA | The 2009-2014 Outlook for Cancer Therapy Pharmaceuticals in the United States | 731 | $495 | |
| USA | The 2009-2014 Outlook for Coronary Vasodilator Pharmaceuticals in the United States | 731 | $495 | |
| USA | The 2009-2014 Outlook for Enema Specialty Laxative Pharmaceutical Preparations in the United States | 448 | $495 | |
| USA | The 2009-2014 Outlook for Estrogen Hormones and Synthetic Substitute Pharmaceuticals in the United States | 748 | $495 | |
| USA | The 2009-2014 Outlook for Fecal Softener Laxative Pharmaceutical Preparations in the United States | 508 | $495 | |
| USA | The 2009-2014 Outlook for Food-Grade Gelatin Excluding Pharmaceutical and Photographic Gelatin in the United States | 705 | $495 | |
| USA | The 2009-2014 Outlook for Insulins and Anti-Diabetic Hormones and Synthetic Substitute Pharmaceuticals in the United States | 749 | $495 | |
| USA | The 2009-2014 Outlook for Irritant Laxative Pharmaceutical Preparations in the United States | 719 | $495 | |
| USA | The 2009-2014 Outlook for Local and Topical Corticoids, Hormones, and Synthetic Hormone Substitute Pharmaceuticals in the United States | 749 | $495 | |
| USA | The 2009-2014 Outlook for Opium and Opium-Derivative Narcotic Internal Analgesic and Antipyretic Pharmaceutical Preparations in the United States | 749 | $495 | |
| USA | The 2009-2014 Outlook for Oral Contraceptive Preparations of Hormones and Synthetic Substitute Pharmaceuticals in the United States | 749 | $495 | |
| USA | The 2009-2014 Outlook for Oxytocic Pharmaceutical Preparations in the United States | 588 | $495 | |
| USA | The 2009-2014 Outlook for Peripheral Vasodilator Pharmaceuticals in the United States | 570 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Cardiovascular System in the United States | 750 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Digestive or Genito-Urinary Systems in the United States | 749 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Human Cardiovascular System in the United States | 749 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Human Digestive and Genitourinary Systems in the United States | 750 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Respiratory System in the United States | 750 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Skin in the United States | 738 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical Preparations Affecting the Central Nervous System and Sense Organs in the United States | 749 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on Skin in the United States | 746 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on the Cardiovascular System in the United States | 749 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on the Central Nervous System and the Sense Organs in the United States | 750 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on the Digestive or the Genito-Urinary Systems in the United States | 749 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on the Respiratory System in the United States | 750 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Affecting Neoplasms, the Endocrine System, and Metabolic Diseases in the United States | 750 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Affecting Parasitic and Ineffective Diseases Excluding Diagnostics in the United States | 749 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Affecting Parasitic and Infectious Diseases Excluding Diagnostics in the United States | 750 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical Preparations for Veterinary Use Excluding Diagnostics in the United States | 749 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical Preparations for Veterinary Use in the United States | 739 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical Vitamin, Nutrient, and Hematinic Preparations for Human Use in the United States | 749 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical Vitamin, Nutrient, and Hematinic Preparations in the United States | 750 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceutical-Grade Gelatin Excluding Unfilled Capsules in the United States | 532 | $495 | |
| USA | The 2009-2014 Outlook for Pharmaceuticals Affecting Neoplasms, the Endocrine System, and Metabolic Diseases in the United States | 750 | $495 | |
| USA | The 2009-2014 Outlook for Rauwolfia-Alkaloid Preparation and Rauwolfia-Diuretic Combination Hypotensive Pharmaceuticals in the United States | 284 | $495 | |
| USA | The 2009-2014 Outlook for Saline Laxative Pharmaceutical Preparations in the United States | 332 | $495 | |
| USA | The 2009-2014 Outlook for Skeletal Muscle Relaxant Pharmaceutical Preparations in the United States | 742 | $495 | |
| USA | The 2009-2014 Outlook for Sulfonamide Pharmaceuticals Excluding Sulfa-Antibiotic Combinations in the United States | 596 | $495 | |
| USA | The 2009-2014 Outlook for Synthetic Antispasmodics and Anticholinergics Pharmaceutical Preparations in the United States | 408 | $495 | |
| USA | The 2009-2014 Outlook for Synthetic Narcotic Pharmaceutical Preparations in the United States | 737 | $495 | |
| USA | The 2009-2014 Outlook for Systemic Antibiotic-Sulfonamide Combination Pharmaceuticals in the United States | 420 | $495 | |
| USA | The 2009-2014 Outlook for Systemic Antiviral Pharmaceuticals in the United States | 731 | $495 | |
| USA | The 2009-2014 Outlook for Systemic Broad-And Medium-Spectrum Antibiotic Pharmaceutical Preparations of Injectable, Semisynthetic Single Penicillins in the United States | 608 | $495 | |
| USA | The 2009-2014 Outlook for Systemic Broad-And Medium-Spectrum Antibiotic Pharmaceutical Preparations of Semisynthetic Single Penicillins Excluding Injectable Forms in the United States | 750 | $495 | |
| USA | The 2009-2014 Outlook for Thyroid and Anti-Thyroid Preparations of Hormones and Synthetic Substitute Pharmaceuticals in the United States | 348 | $495 | |
| USA | The 2009-2014 Outlook for Topical Antibiotic Pharmaceuticals in the United States | 731 | $495 | |
| USA | The 2009-2014 Outlook for Tuberculostatic Isoniazid (isonicotinic Acid Hydrazide) Pharmaceuticals in the United States | 217 | $495 | |
| USA | The 2009-2014 Outlook for Urinary Antibacterials and Antiseptic Pharmaceutical Preparations in the United States | 749 | $495 | |
| USA | The 2009-2014 Outlook for Veterinary Antibiotic Pharmaceuticals Excluding Penicillins and Tetracyclines in the United States | 749 | $495 | |
| USA | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Anesthetics in the United States | 442 | $495 | |
| USA | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Anthelmintics in the United States | 745 | $495 | |
| USA | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Antibiotic Penicillins in the United States | 550 | $495 | |
| USA | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Antibiotic Tetracyclines in the United States | 435 | $495 | |
| USA | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Antiseptics, Wound Dressings, and Fungicides in the United States | 620 | $495 | |
| USA | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of External Parasiticides in the United States | 749 | $495 | |
| USA | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Hemostatics in the United States | 220 | $495 | |
| USA | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Intravenous Solutions and Electrolytes in the United States | 268 | $495 | |
| USA | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Sulfonamides in the United States | 302 | $495 | |
| USA | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Tranquilizers and Ataractics in the United States | 411 | $495 | |
| USA | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Vitamins and Minerals in the United States | 725 | $495 | |
| USA | The 2009-2014 Outlook for Veterinary Pharmaceuticals, Medicinal Premixes, and Medicated Pet Care Products Excluding Diagnostic Preparations and Pet Flea-And-Tick Products in the United States | 752 | $495 | |
| USA | The 2009-2014 Outlook for Glace, Candied, and Crystallized Fruits, Fruit Peels, Nuts, Marshmallow Cream, Cough Drops Excluding Pharmaceutical Type, and Other Confectionery-Type Products in the United States | 772 | $495 | |
| China | The 2009-2014 Outlook for Ace Inhibitor Vasodilator Pharmaceuticals in Greater China | 142 | $495 | |
| China | The 2009-2014 Outlook for Alimentary and Metabolism Pharmaceuticals in Greater China | 142 | $495 | |
| China | The 2009-2014 Outlook for Antacid Pharmaceutical Preparations Excluding Effervescent Salicylate Analgesics in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Anti-Arrhythmic Vasodilator Pharmaceuticals in Greater China | 142 | $495 | |
| China | The 2009-2014 Outlook for Antibacterial and Antiseptic Pharmaceuticals in Greater China | 142 | $495 | |
| China | The 2009-2014 Outlook for Anticoagulant Pharmaceutical Preparations in Greater China | 142 | $495 | |
| China | The 2009-2014 Outlook for Antidepressant Pharmaceuticals in Greater China | 141 | $495 | |
| China | The 2009-2014 Outlook for Antidiarrheal Pharmaceutical Preparations Excluding Narcotics in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Antifungal Pharmaceuticals in Greater China | 141 | $495 | |
| China | The 2009-2014 Outlook for Anti-Infective Pharmaceutical Preparations Affecting Amebacides and Trichomonicides in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Anti-Infective Pharmaceutical Preparations Affecting Anthelminics in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Antimalarial (plasmodicide) Pharmaceuticals in Greater China | 142 | $495 | |
| China | The 2009-2014 Outlook for Anti-Neoplastic Pharmaceutical Agents in Greater China | 141 | $495 | |
| China | The 2009-2014 Outlook for Anti-Neoplastic Radioactive Isotopes for Internal Pharmaceutical Use in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Antispasmodic and Anticholinergic Pharmaceutical Preparations Excluding Synthetic and H2 Blocking Agents in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Antispasmodic and Antisecretory Pharmaceutical Preparations in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Antitubercular Pharmaceuticals Excluding Tuberculostatic Isoniazid (isonicotinic Acid Hydrazide) Preparations in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Beta-Receptor Blocking Agent Hypotensive Pharmaceuticals in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Bronchial Dilator and Anti-Asthmatic Pharmaceutical Preparations in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Calcium Channel Blocker Vasodilator Pharmaceuticals in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Cancer Therapy Pharmaceuticals in Greater China | 141 | $495 | |
| China | The 2009-2014 Outlook for Coronary Vasodilator Pharmaceuticals in Greater China | 141 | $495 | |
| China | The 2009-2014 Outlook for Enema Specialty Laxative Pharmaceutical Preparations in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Estrogen Hormones and Synthetic Substitute Pharmaceuticals in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Fecal Softener Laxative Pharmaceutical Preparations in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Food-Grade Gelatin Excluding Pharmaceutical and Photographic Gelatin in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Glace, Candied, and Crystallized Fruits, Fruit Peels, Nuts, Marshmallow Cream, Cough Drops Excluding Pharmaceutical Type, and Other Confectionery-Type Products in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Insulins and Anti-Diabetic Hormones and Synthetic Substitute Pharmaceuticals in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Irritant Laxative Pharmaceutical Preparations in Greater China | 142 | $495 | |
| China | The 2009-2014 Outlook for Local and Topical Corticoids, Hormones, and Synthetic Hormone Substitute Pharmaceuticals in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Opium and Opium-Derivative Narcotic Internal Analgesic and Antipyretic Pharmaceutical Preparations in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Oral Contraceptive Preparations of Hormones and Synthetic Substitute Pharmaceuticals in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Oxytocic Pharmaceutical Preparations in Greater China | 141 | $495 | |
| China | The 2009-2014 Outlook for Peripheral Vasodilator Pharmaceuticals in Greater China | 141 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Cardiovascular System in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Digestive or Genito-Urinary Systems in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Human Cardiovascular System in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Human Digestive and Genitourinary Systems in Greater China | 145 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Respiratory System in Greater China | 145 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical Preparations Acting on the Skin in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical Preparations Affecting the Central Nervous System and Sense Organs in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on Skin in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on the Cardiovascular System in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on the Central Nervous System and the Sense Organs in Greater China | 146 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on the Digestive or the Genito-Urinary Systems in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Acting on the Respiratory System in Greater China | 145 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Affecting Neoplasms, the Endocrine System, and Metabolic Diseases in Greater China | 145 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Affecting Parasitic and Ineffective Diseases Excluding Diagnostics in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical Preparations for Human Use Affecting Parasitic and Infectious Diseases Excluding Diagnostics in Greater China | 145 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical Preparations for Veterinary Use Excluding Diagnostics in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical Preparations for Veterinary Use in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical Vitamin, Nutrient, and Hematinic Preparations for Human Use in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical Vitamin, Nutrient, and Hematinic Preparations in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceutical-Grade Gelatin Excluding Unfilled Capsules in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Pharmaceuticals Affecting Neoplasms, the Endocrine System, and Metabolic Diseases in Greater China | 145 | $495 | |
| China | The 2009-2014 Outlook for Rauwolfia-Alkaloid Preparation and Rauwolfia-Diuretic Combination Hypotensive Pharmaceuticals in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Saline Laxative Pharmaceutical Preparations in Greater China | 142 | $495 | |
| China | The 2009-2014 Outlook for Skeletal Muscle Relaxant Pharmaceutical Preparations in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Sulfonamide Pharmaceuticals Excluding Sulfa-Antibiotic Combinations in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Synthetic Antispasmodics and Anticholinergics Pharmaceutical Preparations in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Synthetic Narcotic Pharmaceutical Preparations in Greater China | 142 | $495 | |
| China | The 2009-2014 Outlook for Systemic Antibiotic-Sulfonamide Combination Pharmaceuticals in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Systemic Antiviral Pharmaceuticals in Greater China | 141 | $495 | |
| China | The 2009-2014 Outlook for Systemic Broad-And Medium-Spectrum Antibiotic Pharmaceutical Preparations of Injectable, Semisynthetic Single Penicillins in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Systemic Broad-And Medium-Spectrum Antibiotic Pharmaceutical Preparations of Semisynthetic Single Penicillins Excluding Injectable Forms in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Thyroid and Anti-Thyroid Preparations of Hormones and Synthetic Substitute Pharmaceuticals in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Topical Antibiotic Pharmaceuticals in Greater China | 141 | $495 | |
| China | The 2009-2014 Outlook for Tuberculostatic Isoniazid (isonicotinic Acid Hydrazide) Pharmaceuticals in Greater China | 142 | $495 | |
| China | The 2009-2014 Outlook for Urinary Antibacterials and Antiseptic Pharmaceutical Preparations in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Veterinary Antibiotic Pharmaceuticals Excluding Penicillins and Tetracyclines in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Anesthetics in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Anthelmintics in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Antibiotic Penicillins in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Antibiotic Tetracyclines in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Antiseptics, Wound Dressings, and Fungicides in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of External Parasiticides in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Hemostatics in Greater China | 141 | $495 | |
| China | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Intravenous Solutions and Electrolytes in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Sulfonamides in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Tranquilizers and Ataractics in Greater China | 144 | $495 | |
| China | The 2009-2014 Outlook for Veterinary Pharmaceutical Preparations of Vitamins and Minerals in Greater China | 143 | $495 | |
| China | The 2009-2014 Outlook for Veterinary Pharmaceuticals, Medicinal Premixes, and Medicated Pet Care Products Excluding Diagnostic Preparations and Pet Flea-And-Tick Products in Greater China | 145 | $495 | |
| China | The 2009-2014 Outlook for Ophthalmic Pharmaceutical Drugs in Greater China | 141 | $495 | |
| India | The 2009-2014 Outlook for Ophthalmic Pharmaceutical Drugs in India | 319 | $495 | |
| Japan | The 2009-2014 Outlook for Ophthalmic Pharmaceutical Drugs in Japan | 141 | $495 | |
| USA | The 2009-2014 Outlook for Ophthalmic Pharmaceutical Drugs in the United States | 731 | $495 | |
| Title | Pages | Price | Order/View |
|---|---|---|---|
The 2009 Report on Ace Inhibitor Vasodilator Pharmaceuticals: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Alimentary and Metabolism Pharmaceuticals: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Antacid Pharmaceutical Preparations Excluding Effervescent Salicylate Analgesics: World Market Segmentation by City | 341 | $795 | |
The 2009 Report on Anti-Arrhythmic Vasodilator Pharmaceuticals: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Antibacterial and Antiseptic Pharmaceuticals: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Anticoagulant Pharmaceutical Preparations: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Antidepressant Pharmaceuticals: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Antidiarrheal Pharmaceutical Preparations Excluding Narcotics: World Market Segmentation by City | 335 | $795 | |
The 2009 Report on Antifungal Pharmaceuticals: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Anti-Infective Pharmaceutical Preparations Affecting Amebacides and Trichomonicides: World Market Segmentation by City | 341 | $795 | |
The 2009 Report on Anti-Infective Pharmaceutical Preparations Affecting Anthelminics: World Market Segmentation by City | 337 | $795 | |
The 2009 Report on Antimalarial (plasmodicide) Pharmaceuticals: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Anti-Neoplastic Pharmaceutical Agents: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Anti-Neoplastic Radioactive Isotopes for Internal Pharmaceutical Use: World Market Segmentation by City | 339 | $795 | |
The 2009 Report on Antispasmodic and Anticholinergic Pharmaceutical Preparations Excluding Synthetic and H2 Blocking Agents: World Market Segmentation by City | 342 | $795 | |
The 2009 Report on Antispasmodic and Antisecretory Pharmaceutical Preparations: World Market Segmentation by City | 332 | $795 | |
The 2009 Report on Antitubercular Pharmaceuticals Excluding Tuberculostatic Isoniazid (isonicotinic Acid Hydrazide) Preparations: World Market Segmentation by City | 342 | $795 | |
The 2009 Report on Beta-Receptor Blocking Agent Hypotensive Pharmaceuticals: World Market Segmentation by City | 330 | $795 | |
The 2009 Report on Bronchial Dilator and Anti-Asthmatic Pharmaceutical Preparations: World Market Segmentation by City | 338 | $795 | |
The 2009 Report on Calcium Channel Blocker Vasodilator Pharmaceuticals: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Cancer Therapy Pharmaceuticals: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Coronary Vasodilator Pharmaceuticals: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Enema Specialty Laxative Pharmaceutical Preparations: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Estrogen Hormones and Synthetic Substitute Pharmaceuticals: World Market Segmentation by City | 331 | $795 | |
The 2009 Report on Fecal Softener Laxative Pharmaceutical Preparations: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Food-Grade Gelatin Excluding Pharmaceutical and Photographic Gelatin: World Market Segmentation by City | 341 | $795 | |
The 2009 Report on Glace, Candied, and Crystallized Fruits, Fruit Peels, Nuts, Marshmallow Cream, Cough Drops Excluding Pharmaceutical Type, and Other Confectionery-Type Products: World Market Segmentation by City | 354 | $795 | |
The 2009 Report on Insulins and Anti-Diabetic Hormones and Synthetic Substitute Pharmaceuticals: World Market Segmentation by City | 341 | $795 | |
The 2009 Report on Irritant Laxative Pharmaceutical Preparations: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Local and Topical Corticoids, Hormones, and Synthetic Hormone Substitute Pharmaceuticals: World Market Segmentation by City | 341 | $795 | |
The 2009 Report on Logistics for the Pharmaceutical Industry: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Manufacturing Pharmaceutical and Medicinal Products: World Market Segmentation by City | 353 | $795 | |
The 2009 Report on Manufacturing Pharmaceutical Preparations: World Market Segmentation by City | 350 | $795 | |
The 2009 Report on Opium and Opium-Derivative Narcotic Internal Analgesic and Antipyretic Pharmaceutical Preparations: World Market Segmentation by City | 341 | $795 | |
The 2009 Report on Oral Contraceptive Preparations of Hormones and Synthetic Substitute Pharmaceuticals: World Market Segmentation by City | 341 | $795 | |
The 2009 Report on Oxytocic Pharmaceutical Preparations: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Peripheral Vasodilator Pharmaceuticals: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Pharmaceutical Preparations Acting on the Cardiovascular System: World Market Segmentation by City | 338 | $795 | |
The 2009 Report on Pharmaceutical Preparations Acting on the Digestive or Genito-Urinary Systems: World Market Segmentation by City | 344 | $795 | |
The 2009 Report on Pharmaceutical Preparations Acting on the Human Cardiovascular System: World Market Segmentation by City | 342 | $795 | |
The 2009 Report on Pharmaceutical Preparations Acting on the Human Digestive and Genitourinary Systems: World Market Segmentation by City | 343 | $795 | |
The 2009 Report on Pharmaceutical Preparations Acting on the Respiratory System: World Market Segmentation by City | 336 | $795 | |
The 2009 Report on Pharmaceutical Preparations Acting on the Skin: World Market Segmentation by City | 330 | $795 | |
The 2009 Report on Pharmaceutical Preparations Affecting the Central Nervous System and Sense Organs: World Market Segmentation by City | 344 | $795 | |
The 2009 Report on Pharmaceutical Preparations for Human Use Acting on Skin: World Market Segmentation by City | 330 | $795 | |
The 2009 Report on Pharmaceutical Preparations for Human Use Acting on the Cardiovascular System: World Market Segmentation by City | 341 | $795 | |
The 2009 Report on Pharmaceutical Preparations for Human Use Acting on the Central Nervous System and the Sense Organs: World Market Segmentation by City | 343 | $795 | |
The 2009 Report on Pharmaceutical Preparations for Human Use Acting on the Digestive or the Genito-Urinary Systems: World Market Segmentation by City | 341 | $795 | |
The 2009 Report on Pharmaceutical Preparations for Human Use Acting on the Respiratory System: World Market Segmentation by City | 342 | $795 | |
The 2009 Report on Pharmaceutical Preparations for Human Use Affecting Neoplasms, the Endocrine System, and Metabolic Diseases: World Market Segmentation by City | 343 | $795 | |
The 2009 Report on Pharmaceutical Preparations for Human Use Affecting Parasitic and Ineffective Diseases Excluding Diagnostics: World Market Segmentation by City | 342 | $795 | |
The 2009 Report on Pharmaceutical Preparations for Human Use Affecting Parasitic and Infectious Diseases Excluding Diagnostics: World Market Segmentation by City | 344 | $795 | |
The 2009 Report on Pharmaceutical Preparations for Veterinary Use Excluding Diagnostics: World Market Segmentation by City | 339 | $795 | |
The 2009 Report on Pharmaceutical Preparations for Veterinary Use: World Market Segmentation by City | 331 | $795 | |
The 2009 Report on Pharmaceutical Vitamin, Nutrient, and Hematinic Preparations for Human Use: World Market Segmentation by City | 341 | $795 | |
The 2009 Report on Pharmaceutical Vitamin, Nutrient, and Hematinic Preparations: World Market Segmentation by City | 337 | $795 | |
The 2009 Report on Pharmaceutical-Grade Gelatin Excluding Unfilled Capsules: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Pharmaceuticals Affecting Neoplasms, the Endocrine System, and Metabolic Diseases: World Market Segmentation by City | 343 | $795 | |
The 2009 Report on Rauwolfia-Alkaloid Preparation and Rauwolfia-Diuretic Combination Hypotensive Pharmaceuticals: World Market Segmentation by City | 341 | $795 | |
The 2009 Report on Saline Laxative Pharmaceutical Preparations: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Skeletal Muscle Relaxant Pharmaceutical Preparations: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Sulfonamide Pharmaceuticals Excluding Sulfa-Antibiotic Combinations: World Market Segmentation by City | 339 | $795 | |
The 2009 Report on Synthetic Antispasmodics and Anticholinergics Pharmaceutical Preparations: World Market Segmentation by City | 341 | $795 | |
The 2009 Report on Synthetic Narcotic Pharmaceutical Preparations: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Systemic Antibiotic-Sulfonamide Combination Pharmaceuticals: World Market Segmentation by City | 335 | $795 | |
The 2009 Report on Systemic Antiviral Pharmaceuticals: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Systemic Broad-And Medium-Spectrum Antibiotic Pharmaceutical Preparations of Injectable, Semisynthetic Single Penicillins: World Market Segmentation by City | 343 | $795 | |
The 2009 Report on Systemic Broad-And Medium-Spectrum Antibiotic Pharmaceutical Preparations of Semisynthetic Single Penicillins Excluding Injectable Forms: World Market Segmentation by City | 346 | $795 | |
The 2009 Report on Thyroid and Anti-Thyroid Preparations of Hormones and Synthetic Substitute Pharmaceuticals: World Market Segmentation by City | 341 | $795 | |
The 2009 Report on Topical Antibiotic Pharmaceuticals: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Tuberculostatic Isoniazid (isonicotinic Acid Hydrazide) Pharmaceuticals: World Market Segmentation by City | 339 | $795 | |
The 2009 Report on Urinary Antibacterials and Antiseptic Pharmaceutical Preparations: World Market Segmentation by City | 338 | $795 | |
The 2009 Report on Veterinary Antibiotic Pharmaceuticals Excluding Penicillins and Tetracyclines: World Market Segmentation by City | 341 | $795 | |
The 2009 Report on Veterinary Pharmaceutical Preparations of Anesthetics: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Veterinary Pharmaceutical Preparations of Anthelmintics: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Veterinary Pharmaceutical Preparations of Antibiotic Penicillins: World Market Segmentation by City | 336 | $795 | |
The 2009 Report on Veterinary Pharmaceutical Preparations of Antibiotic Tetracyclines: World Market Segmentation by City | 338 | $795 | |
The 2009 Report on Veterinary Pharmaceutical Preparations of Antiseptics, Wound Dressings, and Fungicides: World Market Segmentation by City | 341 | $795 | |
The 2009 Report on Veterinary Pharmaceutical Preparations of External Parasiticides: World Market Segmentation by City | 336 | $795 | |
The 2009 Report on Veterinary Pharmaceutical Preparations of Hemostatics: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Veterinary Pharmaceutical Preparations of Intravenous Solutions and Electrolytes: World Market Segmentation by City | 341 | $795 | |
The 2009 Report on Veterinary Pharmaceutical Preparations of Sulfonamides: World Market Segmentation by City | 329 | $795 | |
The 2009 Report on Veterinary Pharmaceutical Preparations of Tranquilizers and Ataractics: World Market Segmentation by City | 339 | $795 | |
The 2009 Report on Veterinary Pharmaceutical Preparations of Vitamins and Minerals: World Market Segmentation by City | 337 | $795 | |
The 2009 Report on Veterinary Pharmaceuticals, Medicinal Premixes, and Medicated Pet Care Products Excluding Diagnostic Preparations and Pet Flea-And-Tick Products: World Market Segmentation by City | 350 | $795 | |
The 2009 Report on Ophthalmic Pharmaceutical Drugs: World Market Segmentation by City | 329 | $795 | |
Global Trade Perspective Reports:
| Title | Pages | Price | Order/View |
|---|---|---|---|
The World Market for Bread, Baked Goods, Pastry, Cakes, Biscuits, Communion Wafers, Empty Cachets for Pharmaceutical Use, Sealing Wafers, and Rice Paper: A 2009 Global Trade Perspective | 273 | $595 | |
The World Market for Hygenic or Pharmaceutical Articles Made of Unhardened Vulcanized Rubber: A 2009 Global Trade Perspective | 170 | $595 | |
The World Market for Pharmaceutical Goods Excluding Medicaments: A 2009 Global Trade Perspective | 247 | $595 | |
The World Market for Plants and Plants Parts Used Primarily in the Preparation of Perfumes, Pharmaceuticals, Insecticides, and Fungicides: A 2009 Global Trade Perspective | 207 | $595 | |
The World Market for Ambergris, Castoreum, Civit, Musk, Cantharides, Bile, Glands, and Other Animal Products Used in the Preparation of Pharmaceutical Products: A 2009 Global Trade Perspective | 92 | $595 | |
The World Market for Glassware for Laboratory, Hygienic, or Pharmaceutical Use: A 2009 Global Trade Perspective | 162 | $595 | |
| Type | Title | Pages | Price | Order/View |
|---|---|---|---|---|
| Exports | The 2009 World Forecasts of Bread, Baked Goods, Pastry, Cakes, Biscuits, Communion Wafers, Empty Cachets for Pharmaceutical Use, Sealing Wafers, and Rice Paper Export Supplies | 137 | $325 | |
| Exports | The 2009 World Forecasts of Hygenic or Pharmaceutical Articles Made of Unhardened Vulcanized Rubber Export Supplies | 77 | $325 | |
| Exports | The 2009 World Forecasts of Pharmaceutical Goods Excluding Medicaments Export Supplies | 112 | $325 | |
| Exports | The 2009 World Forecasts of Plants and Plants Parts Used Primarily in the Preparation of Perfumes, Pharmaceuticals, Insecticides, and Fungicides Export Supplies | 120 | $325 | |
| Imports | The 2009 World Market Forecasts for Imported Bread, Baked Goods, Pastry, Cakes, Biscuits, Communion Wafers, Empty Cachets for Pharmaceutical Use, Sealing Wafers, and Rice Paper | 158 | $325 | |
| Imports | The 2009 World Market Forecasts for Imported Hygenic or Pharmaceutical Articles Made of Unhardened Vulcanized Rubber | 112 | $325 | |
| Imports | The 2009 World Market Forecasts for Imported Pharmaceutical Goods Excluding Medicaments | 150 | $325 | |
| Imports | The 2009 World Market Forecasts for Imported Plants and Plants Parts Used Primarily in the Preparation of Perfumes, Pharmaceuticals, Insecticides, and Fungicides | 109 | $325 | |
| Imports | The 2009 World Market Forecasts for Imported Ambergris, Castoreum, Civit, Musk, Cantharides, Bile, Glands, and Other Animal Products Used in the Preparation of Pharmaceutical Products | 53 | $325 | |
| Imports | The 2009 World Market Forecasts for Imported Glassware for Laboratory, Hygienic, or Pharmaceutical Use | 107 | $325 | |
| Exports | The 2009 World Forecasts of Ambergris, Castoreum, Civit, Musk, Cantharides, Bile, Glands, and Other Animal Products Used in the Preparation of Pharmaceutical Products Export Supplies | 59 | $325 | |
| Exports | The 2009 World Forecasts of Glassware for Laboratory, Hygienic, or Pharmaceutical Use Export Supplies | 71 | $325 | |
| Title | Pages | Price | Order/View |
|---|---|---|---|
The 2009 Import and Export Market for Bread, Baked Goods, Pastry, Cakes, Biscuits, Communion Wafers, Empty Cachets for Pharmaceutical Use, Sealing Wafers, and Rice Paper in Africa | 51 | $325 | |
The 2009 Import and Export Market for Bread, Baked Goods, Pastry, Cakes, Biscuits, Communion Wafers, Empty Cachets for Pharmaceutical Use, Sealing Wafers, and Rice Paper in Asia | 58 | $325 | |
The 2009 Import and Export Market for Bread, Baked Goods, Pastry, Cakes, Biscuits, Communion Wafers, Empty Cachets for Pharmaceutical Use, Sealing Wafers, and Rice Paper in Europe | 105 | $325 | |
The 2009 Import and Export Market for Bread, Baked Goods, Pastry, Cakes, Biscuits, Communion Wafers, Empty Cachets for Pharmaceutical Use, Sealing Wafers, and Rice Paper in Latin America | 50 | $325 | |
The 2009 Import and Export Market for Bread, Baked Goods, Pastry, Cakes, Biscuits, Communion Wafers, Empty Cachets for Pharmaceutical Use, Sealing Wafers, and Rice Paper in North America & the Caribbean | 39 | $325 | |
The 2009 Import and Export Market for Bread, Baked Goods, Pastry, Cakes, Biscuits, Communion Wafers, Empty Cachets for Pharmaceutical Use, Sealing Wafers, and Rice Paper in Oceana | 31 | $325 | |
The 2009 Import and Export Market for Bread, Baked Goods, Pastry, Cakes, Biscuits, Communion Wafers, Empty Cachets for Pharmaceutical Use, Sealing Wafers, and Rice Paper in the Middle East | 50 | $325 | |
The 2009 Import and Export Market for Hygenic or Pharmaceutical Articles Made of Unhardened Vulcanized Rubber in Africa | 33 | $325 | |
The 2009 Import and Export Market for Hygenic or Pharmaceutical Articles Made of Unhardened Vulcanized Rubber in Asia | 45 | $325 | |
The 2009 Import and Export Market for Hygenic or Pharmaceutical Articles Made of Unhardened Vulcanized Rubber in Europe | 77 | $325 | |
The 2009 Import and Export Market for Hygenic or Pharmaceutical Articles Made of Unhardened Vulcanized Rubber in Latin America | 34 | $325 | |
The 2009 Import and Export Market for Hygenic or Pharmaceutical Articles Made of Unhardened Vulcanized Rubber in North America & the Caribbean | 28 | $325 | |
The 2009 Import and Export Market for Hygenic or Pharmaceutical Articles Made of Unhardened Vulcanized Rubber in Oceana | 22 | $325 | |
The 2009 Import and Export Market for Hygenic or Pharmaceutical Articles Made of Unhardened Vulcanized Rubber in the Middle East | 30 | $325 | |
The 2009 Import and Export Market for Pharmaceutical Goods Excluding Medicaments in Africa | 45 | $325 | |
The 2009 Import and Export Market for Pharmaceutical Goods Excluding Medicaments in Asia | 52 | $325 | |
The 2009 Import and Export Market for Pharmaceutical Goods Excluding Medicaments in Europe | 93 | $325 | |
The 2009 Import and Export Market for Pharmaceutical Goods Excluding Medicaments in Latin America | 50 | $325 | |
The 2009 Import and Export Market for Pharmaceutical Goods Excluding Medicaments in North America & the Caribbean | 31 | $325 | |
The 2009 Import and Export Market for Pharmaceutical Goods Excluding Medicaments in Oceana | 27 | $325 | |
The 2009 Import and Export Market for Pharmaceutical Goods Excluding Medicaments in the Middle East | 45 | $325 | |
The 2009 Import and Export Market for Plants and Plants Parts Used Primarily in the Preparation of Perfumes, Pharmaceuticals, Insecticides, and Fungicides in Africa | 43 | $325 | |
The 2009 Import and Export Market for Plants and Plants Parts Used Primarily in the Preparation of Perfumes, Pharmaceuticals, Insecticides, and Fungicides in Asia | 51 | $325 | |
The 2009 Import and Export Market for Plants and Plants Parts Used Primarily in the Preparation of Perfumes, Pharmaceuticals, Insecticides, and Fungicides in Europe | 81 | $325 | |
The 2009 Import and Export Market for Plants and Plants Parts Used Primarily in the Preparation of Perfumes, Pharmaceuticals, Insecticides, and Fungicides in Latin America | 41 | $325 | |
The 2009 Import and Export Market for Plants and Plants Parts Used Primarily in the Preparation of Perfumes, Pharmaceuticals, Insecticides, and Fungicides in North America & the Caribbean | 30 | $325 | |
The 2009 Import and Export Market for Plants and Plants Parts Used Primarily in the Preparation of Perfumes, Pharmaceuticals, Insecticides, and Fungicides in Oceana | 26 | $325 | |
The 2009 Import and Export Market for Plants and Plants Parts Used Primarily in the Preparation of Perfumes, Pharmaceuticals, Insecticides, and Fungicides in the Middle East | 40 | $325 | |
The 2009 Import and Export Market for Ambergris, Castoreum, Civit, Musk, Cantharides, Bile, Glands, and Other Animal Products Used in the Preparation of Pharmaceutical Products in Africa | 28 | $325 | |
The 2009 Import and Export Market for Ambergris, Castoreum, Civit, Musk, Cantharides, Bile, Glands, and Other Animal Products Used in the Preparation of Pharmaceutical Products in Asia | 32 | $325 | |
The 2009 Import and Export Market for Ambergris, Castoreum, Civit, Musk, Cantharides, Bile, Glands, and Other Animal Products Used in the Preparation of Pharmaceutical Products in Europe | 43 | $325 | |
The 2009 Import and Export Market for Ambergris, Castoreum, Civit, Musk, Cantharides, Bile, Glands, and Other Animal Products Used in the Preparation of Pharmaceutical Products in Latin America | 33 | $325 | |
The 2009 Import and Export Market for Ambergris, Castoreum, Civit, Musk, Cantharides, Bile, Glands, and Other Animal Products Used in the Preparation of Pharmaceutical Products in North America & the Caribbean | 27 | $325 | |
The 2009 Import and Export Market for Ambergris, Castoreum, Civit, Musk, Cantharides, Bile, Glands, and Other Animal Products Used in the Preparation of Pharmaceutical Products in Oceana | 27 | $325 | |
The 2009 Import and Export Market for Ambergris, Castoreum, Civit, Musk, Cantharides, Bile, Glands, and Other Animal Products Used in the Preparation of Pharmaceutical Products in the Middle East | 26 | $325 | |
The 2009 Import and Export Market for Glassware for Laboratory, Hygienic, or Pharmaceutical Use in Africa | 36 | $325 | |
The 2009 Import and Export Market for Glassware for Laboratory, Hygienic, or Pharmaceutical Use in Asia | 45 | $325 | |
The 2009 Import and Export Market for Glassware for Laboratory, Hygienic, or Pharmaceutical Use in Europe | 76 | $325 | |
The 2009 Import and Export Market for Glassware for Laboratory, Hygienic, or Pharmaceutical Use in Latin America | 36 | $325 | |
The 2009 Import and Export Market for Glassware for Laboratory, Hygienic, or Pharmaceutical Use in North America & the Caribbean | 31 | $325 | |
The 2009 Import and Export Market for Glassware for Laboratory, Hygienic, or Pharmaceutical Use in Oceana | 27 | $325 | |
The 2009 Import and Export Market for Glassware for Laboratory, Hygienic, or Pharmaceutical Use in the Middle East | 32 | $325 | |
| Country | Title | Pages | Price | Order/View |
|---|---|---|---|---|
| Australia | Pharmaceutical Industry in Australia: A Strategic Reference, 2003 | 250 | $195 | |
Performance Benchmarking & Productivity Gap Analysis
| Country | Title | Last Updated | Pages | Price | Order/View |
|---|---|---|---|---|---|
| Japan | CHUO BUILD INDUSTRY CO., LTD.: International Competitive Benchmarks and Financial Gap Analysis (others in sector) | 12/2009 | 80 | $210 | |
| Japan | CHUO BUILD INDUSTRY CO., LTD.: Labor Productivity Benchmarks and International Gap Analysis (others in sector) | 12/2009 | 20 | $210 | |
| F, H, J, K, M, N, S, T | |||||
More companies, select a country: | |||||
Value Chain
▼Downstream ▲Upstream
Performance Benchmarking & Productivity Gap Analysis
| Country | Title | Last Updated | Pages | Price | Order/View |
|---|---|---|---|---|---|
| United States | 3-DIMENSIONAL PHARMACEUTICALS, INC.: International Competitive Benchmarks and Financial Gap Analysis (others in sector) | 12/2009 | 80 | $210 | |
| United States | 3-DIMENSIONAL PHARMACEUTICALS, INC.: Labor Productivity Benchmarks and International Gap Analysis (others in sector) | 12/2009 | 60 | $210 | |
| A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Z | |||||
More companies, select a country: | |||||
Value Chain
▼Downstream ▲Upstream
Performance Benchmarking & Productivity Gap Analysis
| Country | Title | Last Updated | Pages | Price | Order/View |
|---|---|---|---|---|---|
| United States | ABAXIS, INC.: International Competitive Benchmarks and Financial Gap Analysis (others in sector) | 12/2009 | 80 | $210 | |
| United States | ABAXIS, INC.: Labor Productivity Benchmarks and International Gap Analysis (others in sector) | 12/2009 | 60 | $210 | |
| United States | ADVANCED MAGNETICS, INC.: International Competitive Benchmarks and Financial Gap Analysis (others in sector) | 12/2009 | 80 | $210 | |
| United States | ADVANCED MAGNETICS, INC.: Labor Productivity Benchmarks and International Gap Analysis (others in sector) | 12/2009 | 60 | $210 | |
| United States | AMERICAN BIO MEDICA CORP.: International Competitive Benchmarks and Financial Gap Analysis (others in sector) | 12/2009 | 24 | $210 | |
| United States | AMERICAN BIO MEDICA CORPORATION: Labor Productivity Benchmarks and International Gap Analysis (others in sector) | 12/2009 | 60 | $210 | |
| United States | AMERICAN BIOGENETIC SCIENCES, INC.: International Competitive Benchmarks and Financial Gap Analysis (others in sector) | 12/2009 | 80 | $210 | |
| United States | AMERICAN BIOGENETIC SCIENCES, INC.: Labor Productivity Benchmarks and International Gap Analysis (others in sector) | 12/2009 | 60 | $210 | |
| United States | AVIGEN, INC.: International Competitive Benchmarks and Financial Gap Analysis (others in sector) | 12/2009 | 24 | $210 | |
| United States | AVIGEN, INC.: Labor Productivity Benchmarks and International Gap Analysis (others in sector) | 12/2009 | 60 | $210 | |
| B, C, D, E, G, H, I, K, L, M, N, O, P, Q, R, S, T, V, Z | |||||
More companies, select a country: | |||||
Value Chain
▼Downstream ▲Upstream
Performance Benchmarking & Productivity Gap Analysis
| Country | Title | Last Updated | Pages | Price | Order/View |
|---|---|---|---|---|---|
| United States | ALBEMARLE CORP.: International Competitive Benchmarks and Financial Gap Analysis (others in sector) | 12/2009 | 24 | $210 | |
| United States | ALBEMARLE CORP.: Labor Productivity Benchmarks and International Gap Analysis (others in sector) | 12/2009 | 20 | $210 | |
| United States | ALCIDE CORP.: International Competitive Benchmarks and Financial Gap Analysis (others in sector) | 12/2009 | 24 | $210 | |
| United States | ALCIDE CORP.: Labor Productivity Benchmarks and International Gap Analysis (others in sector) | 12/2009 | 20 | $210 | |
| B, C, F, I, M, N, Q, S, V | |||||
More companies, select a country: | |||||
Value Chain
▼Downstream ▲Upstream
Performance Benchmarking & Productivity Gap Analysis
| Country | Title | Last Updated | Pages | Price | Order/View |
|---|---|---|---|---|---|
| United States | 3D SYSTEMS CORP.: International Competitive Benchmarks and Financial Gap Analysis (others in sector) | 12/2009 | 80 | $210 | |
| United States | 3D SYSTEMS CORP.: Labor Productivity Benchmarks and International Gap Analysis (others in sector) | 12/2009 | 60 | $210 | |
| A, B, C, D, E, G, I, M, N, P, Q, S, T | |||||
More companies, select a country: | |||||
Value Chain
▼Downstream ▲Upstream
Performance Benchmarking & Productivity Gap Analysis
| Country | Title | Last Updated | Pages | Price | Order/View |
|---|---|---|---|---|---|
| United States | ADVANTAGE MARKETING SYSTEMS, INC.: International Competitive Benchmarks and Financial Gap Analysis (others in sector) | 12/2009 | 24 | $210 | |
| United States | ADVANTAGE MARKETING SYSTEMS, INC.: Labor Productivity Benchmarks and International Gap Analysis (others in sector) | 12/2009 | 20 | $210 | |
| United States | ALLERGY RESEARCH GROUP, INC.: International Competitive Benchmarks and Financial Gap Analysis (others in sector) | 12/2009 | 80 | $210 | |
| United States | ALLERGY RESEARCH GROUP, INC.: Labor Productivity Benchmarks and International Gap Analysis (others in sector) | 12/2009 | 60 | $210 | |
| United States | ALLOU HEALTH & BEAUTY CARE, INC.: International Competitive Benchmarks and Financial Gap Analysis (others in sector) | 12/2009 | 24 | $210 | |
| United States | ALLOU HEALTH & BEAUTY CARE, INC.: Labor Productivity Benchmarks and International Gap Analysis (others in sector) | 12/2009 | 20 | $210 | |
| United States | ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.: International Competitive Benchmarks and Financial Gap Analysis (others in sector) | 12/2009 | 80 | $210 | |
| United States | AMERISOURCEBERGEN CORPORATION: International Competitive Benchmarks and Financial Gap Analysis (others in sector) | 12/2009 | 80 | $210 | |
| United States | AMERISOURCEBERGEN CORPORATION: Labor Productivity Benchmarks and International Gap Analysis (others in sector) | 12/2009 | 60 | $210 | |
| United States | ANDRX CORPORATION: International Competitive Benchmarks and Financial Gap Analysis (others in sector) | 12/2009 | 80 | $210 | |
| United States | ANDRX CORPORATION: Labor Productivity Benchmarks and International Gap Analysis (others in sector) | 12/2009 | 60 | $210 | |
| B, C, D, E, F, J, L, M, O, P, R, S, T | |||||
More companies, select a country: | |||||
Benchmark and Gap Analysis Reports:
| Country | Title | Last Updated | Pages | Price | Order/View |
|---|---|---|---|---|---|
| United States | 3-DIMENSIONAL PHARMACEUTICALS, INC.: International Competitive Benchmarks and Financial Gap Analysis (others in sector) | 12/2009 | 80 | $210 | |
| United States | 3-DIMENSIONAL PHARMACEUTICALS, INC.: Labor Productivity Benchmarks and International Gap Analysis (others in sector) | 12/2009 | 60 | $210 | |
| A, B, C, D, E, F, G, I, K, L, M, N, O, P, Q, R, S, T, V, W | |||||
More companies, select a country: | |||||
For more information about ICON Group International's publications and services, please feel free to contact us:
ICON Group International, Inc.
7404 Trade St.
San Diego, CA 92121
USA
Fax: (858) 635-9414
Email: 
Back | Top | Disclaimers | ICON Home
